156 related articles for article (PubMed ID: 36541221)
41. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
Luminari S; Goldaniga M; Cesaretti M; Orsucci L; Tucci A; Pulsoni A; Salvi F; Arcaini L; Carella AM; Tedeschi A; Pinto A; Stelitano C; Baldini L
Leuk Lymphoma; 2016; 57(4):880-7. PubMed ID: 26379040
[TBL] [Abstract][Full Text] [Related]
42. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
Rummel MJ; Janssens A; MacDonald D; Keating MM; Zaucha JM; Davis J; Lasher J; Babanrao Pisal C; Izquierdo M; Friedberg JW
Br J Haematol; 2021 Jun; 193(6):1123-1133. PubMed ID: 33973233
[TBL] [Abstract][Full Text] [Related]
43. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
44. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
[TBL] [Abstract][Full Text] [Related]
45. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Matsumoto Y; Kobayashi T; Shimura Y; Kawata E; Nagoshi H; Ohshiro M; Sugitani M; Shimura K; Iwai T; Fuchida SI; Yoshida M; Kiyota M; Mizutani S; Chinen Y; Takimoto-Shimomura T; Nakao M; Kaneko H; Uchiyama H; Uoshima N; Nishigaki H; Kobayashi Y; Horiike S; Shimazaki C; Taniwaki M; Kuroda J;
Int J Hematol; 2019 Jul; 110(1):77-85. PubMed ID: 31127456
[TBL] [Abstract][Full Text] [Related]
46. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
47. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
Uchida M; Mori Y; Akiba K; Miyasaka M; Hirano T; Ikesue H; Yamaguchi Y; Takano A; Maegawa N; Shimomura Y; Hosohata K; Muroi N; Ishikawa T; Hashida T; Nakamura T
Biol Pharm Bull; 2020 Oct; 43(10):1577-1582. PubMed ID: 32801282
[TBL] [Abstract][Full Text] [Related]
48. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
49. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
50. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
51. Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Heyman B; Rizzieri D; Adams DJ; De Castro C; Diehl L; Li Z; Moore J; Beaven A
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):679-686. PubMed ID: 30166257
[TBL] [Abstract][Full Text] [Related]
52. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
53. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
[TBL] [Abstract][Full Text] [Related]
54. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
[TBL] [Abstract][Full Text] [Related]
55. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
56. A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
Park BB; Kim WS; Suh C; Hong JY; Yang DH; Lee WS; Do YR; Koh YI; Won JH; Kim MK; Jo JC; Hyun SY; Kim JA; Oh YH; Lee SS
Leuk Lymphoma; 2019 Dec; 60(13):3251-3257. PubMed ID: 31170847
[TBL] [Abstract][Full Text] [Related]
57. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
58. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
[TBL] [Abstract][Full Text] [Related]
59. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Budde LE; Wu D; Martin DB; Philip M; Shustov AR; Smith SD; Gooley TA; Chen TL; Libby EN; Chen EY; Kojouri K; Langerak A; Roden JE; Press OW; Gopal AK
Br J Haematol; 2018 Nov; 183(4):601-607. PubMed ID: 30596402
[TBL] [Abstract][Full Text] [Related]
60. Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R
Izutsu K; Minami Y; Fukuhara N; Terui Y; Jo T; Yamamoto G; Ishikawa T; Kobayashi T; Kiguchi T; Nagai H; Ohtsu T; Kalambakas S; Fustier P; Midorikawa S; Tobinai K
Int J Hematol; 2020 Mar; 111(3):409-416. PubMed ID: 31858429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]